14 minutes agoThe FDA sanctioned trial for remestemce-L is very intensive and incredibly detailed.
https://www.clinicaltrials.gov/ct2/show/NCT04371393?term=remestemcel-L&cond=COVID-19&draw=2&rank=3ThePrimary outcomes measure is: "Number of all-cause mortality within 30 days of randomization".The secondary outcomes measures are:There are 35 secondary data points, too many to list here. The message here is: Mesoblast is being very thorough with their trial and they are covering all the bases. They seriously intend to get this approved by the FDA on the first shot, without questions or doubts...
Glta
- Forums
- ASX - By Stock
- MSB
- Ann: EAP for Remestemcel-L in Children with MIS-C due to COVID-19
Ann: EAP for Remestemcel-L in Children with MIS-C due to COVID-19, page-252
-
- There are more pages in this discussion • 174 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.15 |
Change
-0.105(8.37%) |
Mkt cap ! $1.313B |
Open | High | Low | Value | Volume |
$1.22 | $1.23 | $1.14 | $9.583M | 8.106M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | $1.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.16 | 25000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 1.150 |
9 | 110632 | 1.145 |
11 | 486131 | 1.140 |
2 | 74852 | 1.135 |
8 | 295301 | 1.130 |
Price($) | Vol. | No. |
---|---|---|
1.155 | 25000 | 2 |
1.160 | 25000 | 1 |
1.165 | 48667 | 3 |
1.170 | 38440 | 2 |
1.175 | 39740 | 4 |
Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |